We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+17.52%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$22.3M
Cap. Flow
+$13.3M
Cap. Flow %
11.44%
Top 10 Hldgs %
63.03%
Holding
49
New
5
Increased
5
Reduced
1
Closed
11

Top Buys

Rank Stock Value
1
BSLK
Bolt Projects Holdings
BSLK
+$3.9M
2
ZLAB icon
Zai Lab
ZLAB
+$3.4M
3
CLYM
Climb Bio
CLYM
+$3.28M
4
SLNO
Soleno Therapeutics
SLNO
+$3.06M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.04M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$814K
2
LONA
LeonaBio Inc
LONA
+$477K
3
PACB icon
Pacific Biosciences
PACB
+$376K
4
CABA icon
Cabaletta Bio
CABA
+$353K
5
ROIV icon
Roivant Sciences
ROIV
+$343K

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Materials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
1
Illumina
ILMN
$31B
$15.5M 13.39%
119,196
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$14.7M 12.7%
368,665
– –
GERN icon
3
Geron
GERN
$828M
$6.24M 5.37%
1,373,550
– –
MRUS
4
DELISTED
Merus
MRUS
$6M 5.17%
120,038
– –
ZLAB icon
5
Zai Lab
ZLAB
$2.06B
$5.67M 4.89%
235,000
+180,000
+327% +$3.4M
LBPH
6
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.35M 4.61%
160,570
+16,000
+11% +$551K
OCS icon
7
Oculis Holding
OCS
$683M
$5.35M 4.61%
436,378
– –
ONC
8
BeOne Medicines Ltd
ONC
$32.8B
$5.17M 4.45%
23,022
– –
INCY icon
9
Incyte
INCY
$24.2B
$4.89M 4.22%
74,022
– –
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.06B
$4.2M 3.62%
106,680
– –
EXAI
11
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.2M 3.62%
859,892
– –
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.46B
$4.14M 3.57%
106,100
– –
TRML
13
DELISTED
Tourmaline Bio
TRML
$3.77M 3.25%
146,800
– –
LAB icon
14
Standard BioTools
LAB
$340M
$3.63M 3.13%
1,883,179
– –
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$3.23M 2.78%
+63,950
New +$3.06M
REPL icon
16
Replimune Group
REPL
$941M
$3.15M 2.72%
287,846
+82,907
+40% +$842K
RYTM icon
17
Rhythm Pharmaceuticals
RYTM
$6.81B
$2.57M 2.22%
49,120
– –
CLYM
18
Climb Bio
CLYM
$681M
$2.36M 2.03%
+463,654
New +$3.28M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$10.8B
$2.07M 1.78%
9,762
+4,080
+72% +$1.04M
ASND icon
20
Ascendis Pharma A/S
ASND
$16B
$2.03M 1.75%
13,600
– –
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$1.79M 1.54%
154,522
-64,755
-30% -$814K
EXEL icon
22
Exelixis
EXEL
$13.3B
$1.67M 1.44%
64,200
– –
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.43B
$1.58M 1.36%
102,984
– –
RANI icon
24
Rani Therapeutics
RANI
$87M
$1.07M 0.92%
493,584
– –
TRDA icon
25
Entrada Therapeutics
TRDA
$264M
$784K 0.68%
49,082
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q3 2024 Portfolio in Review

As of Q3 2024, Nan Fung Group Holdings held 49 positions worth $116M, up 24% from $93.7M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Nan Fung Group Holdings deployed $13.3M of net new capital in Q3 2024, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Bolt Projects Holdings: 40,598 shares worth $666K.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was KalVista Pharmaceuticals, an estimated $814K trimmed.

  • Nan Fung Group Holdings's largest Q3 2024 buy was Bolt Projects Holdings: 40,598 shares worth $666K.
  • Nan Fung Group Holdings added most to Zai Lab in Q3 2024, an estimated $3.4M increase.
  • Nan Fung Group Holdings's biggest Q3 2024 reduction was KalVista Pharmaceuticals, cutting an estimated $814K.
  • Nan Fung Group Holdings fully exited LeonaBio Inc in Q3 2024, selling an estimated $477K.
  • Nan Fung Group Holdings's ten largest holdings make up 63% of its $116M portfolio in Q3 2024.
  • Nan Fung Group Holdings opened 5 new positions and closed 11 in Q3 2024.
  • Nan Fung Group Holdings's portfolio value rose 24% quarter-over-quarter to $116M.

Based on Nan Fung Group Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.